Sinovac's Covid-19 vaccine: Old but still gold?


Modified 21 Jun 2021, 10:07 am

KINIGUIDE | Of the three Covid-19 vaccines currently in use in the government’s National Covid-19 Immunisation Programme (NIP), perhaps one of the more divisive ones is Sinovac’s CoronaVac.

On one hand, some view it as an inferior product compared to mRNA vaccines like Pfizer-BioNTech’s Comirnaty due to its poor efficacy in trials, especially when CoronaVac was tested in Brazil.

Meanwhile, proponents view it as a safer vaccine because it was manufactured using the tried-and-true method of inactivating viruses, as opposed to mRNA vaccines (like Comirnaty) and viral vector vaccines (like AstraZeneca-Oxford’s Vaxzevria and CanSino Biologic’s Convidecia) that are relatively new.

The conversation online is further inflamed by the politics surrounding vaccines and their perceived country of origin.

For this instalment of KiniGuide, we cut through the noise to look at the facts and data regarding the vaccine...

Already Subscribed? Sign In
All Access Plan
from ~RM12 / month
Unlimited access to our articles
Comment on all our stories
Gift articles to your friends
Secure and Encrypted
Student or Senior Citizen? Get a special rateGroup / Institutional / Corporate Plans